申请人:Daiichi Sankyo Co., Ltd.
公开号:EP3130608A1
公开(公告)日:2017-02-15
As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH-(CH2)n1-La-Lb-Lc or -L1-L2-LP-wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.
作为一种抗肿瘤效果和安全性极佳且治疗效果极佳的抗肿瘤药物,本发明提供了一种抗体-药物共轭物,其中下式表示的抗肿瘤化合物通过具有下式表示的结构的连接体与抗 HER2 抗体共轭:L1-L2-LP-NH-(CH2)n1-La-Lb-Lc或-L1-L2-LP-其中,抗 HER2 抗体与末端 L1 连接,抗肿瘤化合物与末端 Lc 或 LP 连接,连接位置为 1 位氨基的氮原子。